Analysts Set Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Target Price at $43.20

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has earned an average rating of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $45.6667.

Several equities research analysts recently commented on the company. Citigroup reaffirmed a “buy” rating on shares of Rigel Pharmaceuticals in a research report on Wednesday, January 14th. Wall Street Zen upgraded shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, December 21st. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a report on Thursday, January 22nd. Finally, Zacks Research upgraded shares of Rigel Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 18th.

Rigel Pharmaceuticals Stock Down 2.2%

Rigel Pharmaceuticals stock opened at $28.87 on Wednesday. Rigel Pharmaceuticals has a 12 month low of $15.50 and a 12 month high of $52.24. The stock has a fifty day simple moving average of $36.85 and a two-hundred day simple moving average of $37.24. The company has a current ratio of 2.42, a quick ratio of 2.14 and a debt-to-equity ratio of 0.06. The firm has a market cap of $533.23 million, a price-to-earnings ratio of 1.53 and a beta of 1.10.

Key Headlines Impacting Rigel Pharmaceuticals

Here are the key news stories impacting Rigel Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright sharply raised its FY2026 EPS forecast to $4.73 from $3.14, signaling much stronger near-term profitability expectations that could support higher valuation if realized.
• Neutral Sentiment: HC Wainwright published detailed quarterly 2026 forecasts (Q1: $0.95, Q2: $1.20, Q3: $1.27, Q4: $1.30) that provide a clear earnings cadence for the year but reflect forward modeling assumptions investors should verify against company guidance and pipeline progress.
• Neutral Sentiment: The company’s recent earnings call transcript offers management commentary and operational detail investors should review to reconcile analyst projections with product, revenue and margin drivers. Rigel Pharma (RIGL) Earnings Call Transcript
• Negative Sentiment: Rigel disclosed significant uncertainty around pursuing FDA fast-track designation for its programs, which raises regulatory execution risk that could delay approvals or returns and pressure the stock. Rigel Pharmaceuticals’ Fast Track Ambitions Face Significant FDA Uncertainty

Insider Transactions at Rigel Pharmaceuticals

In related news, Director Walter H. Moos sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $36.36, for a total value of $145,440.00. Following the sale, the director owned 12,722 shares in the company, valued at approximately $462,571.92. This trade represents a 23.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 9.48% of the company’s stock.

Institutional Investors Weigh In On Rigel Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in RIGL. AlphaQuest LLC lifted its holdings in shares of Rigel Pharmaceuticals by 234.8% during the 3rd quarter. AlphaQuest LLC now owns 1,105 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 775 shares during the period. Laurel Wealth Advisors LLC boosted its stake in shares of Rigel Pharmaceuticals by 1,773.3% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 2,810 shares of the biotechnology company’s stock worth $53,000 after buying an additional 2,660 shares during the last quarter. IFP Advisors Inc bought a new stake in shares of Rigel Pharmaceuticals in the third quarter worth $55,000. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Rigel Pharmaceuticals by 400.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,275 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 1,020 shares during the period. Finally, Caitong International Asset Management Co. Ltd bought a new position in Rigel Pharmaceuticals in the third quarter valued at about $62,000. 66.23% of the stock is currently owned by hedge funds and other institutional investors.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).